Acute cholangitis following mRNA COVID-19 vaccine booster in a patient receiving an anti-amyloid antibody for Alzheimer’s disease: A case report

Linda L. Restifo; Robert P. Erickson

doi:10.1177/2050313X231194507

Acute cholangitis following mRNA COVID-19 vaccine booster in a patient receiving an anti-amyloid antibody for Alzheimer’s disease: A case report

Linda L. Restifo, Robert P. Erickson

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

A 77-year-old woman had 2 weeks of fever and flu-like symptoms starting several hours after receiving an mRNA booster for SARS-CoV-2 and the influenza vaccine, in separate shots. Laboratory tests showed cholangitis. Medical history included APOE-ε4 carrier genotype, mild Alzheimer’s disease, participation in a clinical trial of aducanumab, and resolving polymyalgia rheumatica. The patient recovered with at-home supportive care. She had aducanumab-associated amyloid-related imaging abnormalities–edema (ARIA-E) both before and after the acute cholangitis. Two months following the vaccinations polymyalgia rheumatica recurred. This case raises questions about interactions among immune-mediated disease, complications of anti-amyloid monoclonal antibodies, and adverse events following SARS-CoV-2 mRNA vaccination.

Original language	English (US)
Journal	SAGE Open Medical Case Reports
Volume	11
DOIs	https://doi.org/10.1177/2050313X231194507
State	Published - Jan 1 2023

Keywords

APOE
ARIA-E
Aducanumab
SARS-CoV-2 mRNA vaccine
adverse event
polymyalgia rheumatica

ASJC Scopus subject areas

General Medicine

Access to Document

10.1177/2050313X231194507

Cite this

@article{502a807d430747c7bf153390a6b3864e,

title = "Acute cholangitis following mRNA COVID-19 vaccine booster in a patient receiving an anti-amyloid antibody for Alzheimer{\textquoteright}s disease: A case report",

abstract = "A 77-year-old woman had 2 weeks of fever and flu-like symptoms starting several hours after receiving an mRNA booster for SARS-CoV-2 and the influenza vaccine, in separate shots. Laboratory tests showed cholangitis. Medical history included APOE-ε4 carrier genotype, mild Alzheimer{\textquoteright}s disease, participation in a clinical trial of aducanumab, and resolving polymyalgia rheumatica. The patient recovered with at-home supportive care. She had aducanumab-associated amyloid-related imaging abnormalities–edema (ARIA-E) both before and after the acute cholangitis. Two months following the vaccinations polymyalgia rheumatica recurred. This case raises questions about interactions among immune-mediated disease, complications of anti-amyloid monoclonal antibodies, and adverse events following SARS-CoV-2 mRNA vaccination.",

keywords = "APOE, ARIA-E, Aducanumab, SARS-CoV-2 mRNA vaccine, adverse event, polymyalgia rheumatica",

author = "Restifo, {Linda L.} and Erickson, {Robert P.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023.",

year = "2023",

month = jan,

day = "1",

doi = "10.1177/2050313X231194507",

language = "English (US)",

volume = "11",

journal = "SAGE Open Medical Case Reports",

issn = "2050-313X",

publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Acute cholangitis following mRNA COVID-19 vaccine booster in a patient receiving an anti-amyloid antibody for Alzheimer’s disease

T2 - A case report

AU - Restifo, Linda L.

AU - Erickson, Robert P.

N1 - Publisher Copyright: © The Author(s) 2023.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - A 77-year-old woman had 2 weeks of fever and flu-like symptoms starting several hours after receiving an mRNA booster for SARS-CoV-2 and the influenza vaccine, in separate shots. Laboratory tests showed cholangitis. Medical history included APOE-ε4 carrier genotype, mild Alzheimer’s disease, participation in a clinical trial of aducanumab, and resolving polymyalgia rheumatica. The patient recovered with at-home supportive care. She had aducanumab-associated amyloid-related imaging abnormalities–edema (ARIA-E) both before and after the acute cholangitis. Two months following the vaccinations polymyalgia rheumatica recurred. This case raises questions about interactions among immune-mediated disease, complications of anti-amyloid monoclonal antibodies, and adverse events following SARS-CoV-2 mRNA vaccination.

AB - A 77-year-old woman had 2 weeks of fever and flu-like symptoms starting several hours after receiving an mRNA booster for SARS-CoV-2 and the influenza vaccine, in separate shots. Laboratory tests showed cholangitis. Medical history included APOE-ε4 carrier genotype, mild Alzheimer’s disease, participation in a clinical trial of aducanumab, and resolving polymyalgia rheumatica. The patient recovered with at-home supportive care. She had aducanumab-associated amyloid-related imaging abnormalities–edema (ARIA-E) both before and after the acute cholangitis. Two months following the vaccinations polymyalgia rheumatica recurred. This case raises questions about interactions among immune-mediated disease, complications of anti-amyloid monoclonal antibodies, and adverse events following SARS-CoV-2 mRNA vaccination.

KW - APOE

KW - ARIA-E

KW - Aducanumab

KW - SARS-CoV-2 mRNA vaccine

KW - adverse event

KW - polymyalgia rheumatica

UR - http://www.scopus.com/inward/record.url?scp=85169425843&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85169425843&partnerID=8YFLogxK

U2 - 10.1177/2050313X231194507

DO - 10.1177/2050313X231194507

M3 - Article

AN - SCOPUS:85169425843

SN - 2050-313X

VL - 11

JO - SAGE Open Medical Case Reports

JF - SAGE Open Medical Case Reports

ER -

Acute cholangitis following mRNA COVID-19 vaccine booster in a patient receiving an anti-amyloid antibody for Alzheimer’s disease: A case report

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this